Literature DB >> 10891534

Expression analysis and mutational screening of the epithelium-specific ets gene-1 (ESE-1) in patients with squamous anal cancer.

C Zucchini1, P Strippoli, G Rosati, M Del Governatore, E Milano, G Ugolini, R Solmi, G Mattei, A Caira, S Zanotti, P Carinci, L Valvassori.   

Abstract

To investigate whether ESE-1 gene abnormalities are involved in alterations of epithelial cell differentiation in squamous anal cancer ESE-1 expression and structure were screened in six patients by reverse transcriptase-polymerase chain reaction (RT-PCR) and automated sequence analysis. The complete cDNA of isoform ESE-1b was always expressed and correctly spliced, with single nucleotide polymorphism being observed in two cases. Presence of ESE-1b point mutations was excluded. Expression of SPRR2A and ENDOA/CK8, two epithelium-specific ESE-1 target genes, were revealed by RT-PCR in all cases. This first report of expression of ESE-1, and of SPRR2A and ENDOA/CK8 (both related to terminal differentiation in different types of epithelia lining) in anal cancer excludes the hypothesis that these genes influenced carcinogenesis in our patients. Despite selecting of patients without clinical evidence of HPV infection, PCR consistently revealed HPV-16 DNA, highlighting the importance of HPV infection in anal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891534     DOI: 10.3892/ijo.17.2.265

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Serum Small Proline-Rich Protein 2A (SPRR2A) Is a Noninvasive Biomarker in Gastric Cancer.

Authors:  Xiaoming Xu; Shumei Wei; Yueming Chen; Daojun Yu; Xianjun Wang; Xueyan Dong
Journal:  Dis Markers       Date:  2020-08-28       Impact factor: 3.434

2.  Small Proline-Rich Protein 2B Facilitates Gastric Adenocarcinoma Proliferation via MDM2-p53/p21 Signaling Pathway.

Authors:  Ling Yao; Jinhua Yan; Fei Cheng; Lihong Gan; Yaqin Huang; Li Zheng; Nian Fang
Journal:  Onco Targets Ther       Date:  2021-02-26       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.